AstraZeneca

Live view: Yahoo

Identity (GLEIF Global LEI Index)

Field	Value	Class
Legal name	AstraZeneca	SF
LEI	Unavailable	SF
Swiss UID	Not in GLEIF record	SF
Jurisdiction	Unavailable	SF
Legal address	Unavailable	SF
Headquarters		SF
Entity status	Unavailable	SF
Geneva connection	unresolved	CM

ⓘ

Listed securities (SIX Swiss Exchange issuer directory)

ISIN	Ticker	MIC	Share class	Segment	Accounting standard	Next GM	Auditor	Prov.
	AZN				—	not announced	—	ⓘ

Market snapshot

12594.00 GBp
Stale — 14 days old · delayed per exchange agreement · yahoo

Metric	Value	Class
SMA 20	13603.50	CM
SMA 50	13606.92	CM
52-week range position	44% of range 10232.00–15542.00	CM
Trend (SMA20 vs SMA50)	sideways	CM
History depth	254 daily bars	SF

Analyst price targets

Low	Mean	Median	High	Analysts	Provider	As of
11294.985	15767.113	16171.271	18424.404	22	yfinance	2026-07-19T11:08:10Z

Consensus recommendation (provider-published): buy

Financials (latest reported period)

Most recent reported income-statement figures (company disclosure redistributed by the named source); absent figures stay absent — never estimated.

Period ending 2025-12-31 (annual) · reported in USD

Metric	Value	Class
Revenue	58.7B USD	SF
Gross profit	48.1B USD	SF
Operating income	13.3B USD	SF
EBITDA	19.5B USD	SF
Net income	10.2B USD	SF
EPS	6.54	SF

ⓘ

2 further data fields this platform tracks — no connected source covers this issuer yet. Shown to demonstrate capacity; each populates automatically when a source does, and nothing is estimated in the meantime. Show what is tracked ›

Recent company events

News, insider transactions, congressional trading disclosures and analyst-estimate snapshots from connected sources, each with provenance. Analyst estimates are forecasts — never price targets.

No company events ingested yet — the FMP rotation families (news, insider transactions, congressional disclosures, analyst estimates) populate this once a key is configured. Nothing is invented in the meantime.

Segment & geographic revenue (company disclosures)

Figures parsed from filings and redistributed by the named provider; values are shown as reported and shares are Calculated Metrics with the formula in the column header.

No disclosed segment or geographic revenue ingested for this company yet. The Business Quant pipeline (SEC-parsed company disclosures) reaches US-listed issuers progressively within its daily budget; issuers that do not disclose segment detail keep this honest state.

How the company makes money

Business description and sector are sourced facts (Yahoo assetProfile / Wikidata / Wikipedia — source named per value); the registry-disclosed purpose follows. Disclosed segment/geographic revenue appears in the card above when the issuer reports it; official EDGAR-XBRL and ESEF facts feed the financials card since 2026-07-07. Nothing is estimated in the meantime.

AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. SF
source: wikipedia · retrieved 2026-07-19

Sector: pharmaceutical industry peers

Registry-disclosed purpose: Access currently requires credentials — the Swiss registry (Zefix) API returned HTTP 401 anonymously (verified 2026-07-02); registered-purpose text will populate once free Zefix credentials are configured in .env.

Regulators of highest concern

Ranked by maximum applicability of evidence-backed matches; when none exist yet, the jurisdictional supervision context derived from listing venue/domicile is shown instead — labelled, never asserted as a match.

Authority	Jur.	Matches	Max applicability	Max confidence
Health and Human Services Department	US	7	0.65	0.78
EU Publications Office (EU law)	EU	1	0.65	0.78

Regulatory exposure — matches with evidence

The price-impact column is a LABELLED INFERENCE (EBI): reasoning about whether and why the exposure could bear on the share price, derived from the regulation's type, region and topic and the match layer/direction. It is not an asserted fact and states no magnitude; the Applicability/Confidence/Exposure figures and the linked evidence remain the sourced basis.

Rule	Instrument	Relationship	Applicability	Confidence	Exposure	Potential price impact (inference)	Review
R-SECTOR-PHARMA_HEALTH	Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced	sector_topic_candidate_pharma_health	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-PHARMA_HEALTH	Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for	sector_topic_candidate_pharma_health	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-PHARMA_HEALTH	Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Abs	sector_topic_candidate_pharma_health	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-PHARMA_HEALTH	Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant S	sector_topic_candidate_pharma_health	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-PHARMA_HEALTH	Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerv	sector_topic_candidate_pharma_health	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-PHARMA_HEALTH	Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regardin	sector_topic_candidate_pharma_health	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-PHARMA_HEALTH	CELEX:32026R1451: Commission Delegated Regulation (EU) 2026/1451 of 20 March 2026 amending	sector_topic_candidate_pharma_health	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a EU pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review
R-SECTOR-PHARMA_HEALTH	Recission of the National Cancer Institute Clinical Cancer Education Program Regulation	sector_topic_candidate_pharma_health	0.65	0.78	Insufficient evidence to calculate	EBI Limited direct impact. An indirect topical (candidate) link to a US pharma / health measure: if it applied it could affect approval and compliance costs, or market access for regulated products, but any effect would be indirect and is unconfirmed. The measure is proposed / not yet in force, so any impact would be prospective and contingent on adoption. Inference from the match's regulation type, region and topic — not an asserted fact; no magnitude implied.	needs_review

Recent filings — potential impact inputs

A filing flags potential impact only via evidence-backed matching between its disclosed content and tracked measures.

Filed	Form	Title	Document
2026-07-01	6-K	6-K — ASTRAZENECA PLC	document
2026-07-01	6-K	6-K — ASTRAZENECA PLC	document
2026-06-29	6-K	6-K — ASTRAZENECA PLC	document
2026-06-29	6-K	6-K — ASTRAZENECA PLC	document
2026-06-15	6-K	6-K — ASTRAZENECA PLC	document
2026-06-01	6-K	6-K — ASTRAZENECA PLC	document
2026-06-01	6-K	6-K — ASTRAZENECA PLC	document
2026-05-29	6-K	6-K — ASTRAZENECA PLC	document
2026-05-27	6-K	6-K — ASTRAZENECA PLC	document
2026-05-26	6-K	6-K — ASTRAZENECA PLC	document